Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Blood (2019) 134 (Supplement_1): 109.

https://doi.org/10.1182/blood-2019-122483

Published: 2019

Journal Articles

Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control

Blood (2019) 134 (Supplement_1): 279.

https://doi.org/10.1182/blood-2019-123464

Published: 2019

Journal Articles

The Lysine Histone Methyltransferase SETD2 Is Required for Appropriate Immunoglobulin VDJ Recombination

S. Haihua Chu, PhD, Jonathan Chabon, BS, Janna Minehart, BS, Chloe N Matovina, BS, Jian Zhang, Bo-Ruei Chen, PhD, Elsa Callen-Moreu, PhD, Putzer J Hung, Zhaohui Feng, BM, BS, Richard Koche, PhD, X. Shirley Liu, Jayanta Chaudhuri, Andre Nussenzweig, PhD, Barry Sleckman, Scott A. Armstrong, MD PhD

Blood (2018) 132 (Supplement 1): 511.

https://doi.org/10.1182/blood-2018-99-111952

Published: 2018

Journal Articles

Functional Profiling of Patient AML Stem Cells Reveals Mechanisms of Epigenetic Plasticity Controlling Therapy Resistance

Sumiko Takao, MD PhD, Richard Koche, PhD, Paolo Cifani, PhD, Zheng Ser, Alex Kentsis, MD PhD

Blood (2018) 132 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2018-99-114433

Published: 2018

Journal Articles

AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival

Katya Ahr, BA, Christopher Famulare, MS, Richard Koche, PhD, Barbara Spitzer, MD, Ross L. Levine, MD, Martin S. Tallman, MD, Aaron D Goldberg, MD PhD, Eytan M. Stein, MD, Jacob L Glass, MD PhD

Blood (2018) 132 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2018-99-118407

Published: 2018

Journal Articles

Targeting the DNA Damage Response Pathway in MLL- rearranged B-Acute Lymphoblastic Leukemias

S. Haihua Chu, PhD, Evelyn Junyao Song, BS, Jonathan Chabon, BS, Janna Minehart, BS, Zhaohui Feng, BM, BS, Kenneth Ross, PhD, Richard Koche, PhD, Andrei V. Krivtsov, PhD, Scott Armstrong, MD PhD

Blood (2017) 130 (Supplement 1): 3880.

https://doi.org/10.1182/blood.V130.Suppl_1.3880.3880

Published: 2017

Journal Articles

Lineage Deconvolution Using Chromatin Accessibility and DNA Methylation Shows a Spectrum of Lineage Characteristics and Differentiation States across Acute Leukemias

Jacob L Glass, MDPhD, Alyson J Palia, Francine E. Garrett-Bakelman, MDPhD, Richard Koche, PhD, Ross L. Levine, MD, Martin S. Tallman, MD, Richard James Dillon, MA, PhD MRCP, FRCPath, David Grimwade, Adolfo A. Ferrando, MD PhD, Peter J.M. Valk, PhD, Ruud Delwel, PhD, Maria E. Figueroa, MD, Ari Melnick, MD, Olivier Elemento, PhD

Blood (2017) 130 (Supplement 1): 1208.

https://doi.org/10.1182/blood.V130.Suppl_1.1208.1208

Published: 2017

Journal Articles

LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebpα-Dependent Enhancers in AML

Monica Cusan, MD, Sheng Cai, MD PhD, Helai P Mohammad, PhD, Andrei V. Krivtsov, PhD, Alan Chramiec, Evangelia Loizou, Daniel G. Tenen, MD, Min Ye, PhD, Britta Will, PhD, Ulrich G. Steidl, MDPhD, Ryan G. Kruger, PhD, Richard Koche, PhD, Scott Armstrong, MD PhD

Blood (2017) 130 (Supplement 1): 242.

https://doi.org/10.1182/blood.V130.Suppl_1.242.242

Published: 2017

Journal Articles

Inhibition of MEK and DDR Pathways Induces Synergistic Killing of Novel Mll-Af4 B-ALL Model Harboring Activated Ras Mutations

Evelyn J Song, BS, S. Haihua Chu, PhD, Janna Minehart, BS, Jonathan Chabon, BS, Richard Koche, PhD, Andrei Krivtsov, PhD, Scott A. Armstrong, MD PhD

Blood (2016) 128 (22): 1511.

https://doi.org/10.1182/blood.V128.22.1511.1511

Published: 2016

Journal Articles

An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL -Rearranged Leukemia to DOT1L Inhibition

Blood (2016) 128 (22): 571.

https://doi.org/10.1182/blood.V128.22.571.571

Published: 2016

Journal Articles

Loss of Lysine Histone Methyltransferase Setd2 Disrupts Normal Hematopoiesis, Lineage Commitment and Reveals a Novel Role for H3K36me3 in Immunoglobulin VDJ Recombination

S. Haihua Chu, PhD, Jonathan R Chabon, BS, Janna Minehart, BS, Richard Koche, PhD, Katie Li, BS, Matthew Witkin, BS, Andrei Krivtsov, PhD, Scott A. Armstrong, MD PhD

Blood (2016) 128 (22): 423.

https://doi.org/10.1182/blood.V128.22.423.423

Published: 2016

Journal Articles

Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia

Kavitha Ramaswamy, MD, Lauren Forbes, Fiona C Brown, PhD, Richard Koche, PhD, Tatyana Gindin, MDPhD, Gerard Minuesa, PhD, Michael G. Kharas, PhD, Andrei Krivtsov, PhD, Scott A. Armstrong, MD PhD, Eric Still, Elisa de Stanchina, PhD, Randi Isenhart, Guangwu Guo, Birgit Knoechel, MDPhD, Alex Kentsis, MD PhD

Blood (2016) 128 (22): 3945.

https://doi.org/10.1182/blood.V128.22.3945.3945

Published: 2016

Journal Articles

Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia

Fiona C Brown, PhD, Eric Still, Paolo Cifani, PhD, Casie Reed, Scott Ficarro, PhD, Jie He, PhD, Richard Koche, PhD, Patrick Bhola, PhD, Peter Romanienko, PhD, Willie Mark, PhD, Andrei V. Krivtsov, PhD, Anthony Letai, MD PhD, Nathanael Gray, PhD, Jarrod Marto, PhD, Scott A. Armstrong, MD PhD, Alex Kentsis, MD PhD

Blood (2016) 128 (22): 436.

https://doi.org/10.1182/blood.V128.22.436.436

Published: 2016

Journal Articles

Non-Catalytic Role of SETD1A Regulates DNA Repair in Leukemia

Takayuki Hoshii, PhD, Paolo Cifani, PhD, Tomoyoshi Nakadai, PhD, Zhaohui Feng, BM, BS, Chun-Hao Huang, PhD, Richard Koche, PhD, Christopher D Delaney, Chun-Wei David Chen, PhD, Scott W. Lowe, PhD, Robert Roeder, PhD, Alex Kentsis, MD PhD, Scott A. Armstrong, MD PhD

Blood (2016) 128 (22): 434.

https://doi.org/10.1182/blood.V128.22.434.434

Published: 2016

Journal Articles

BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes

Lindsay M LaFave, PhD, Wendy Béguelin, PhD, Richard Koche, PhD, Matt Teater, Efthymia Papalexi, Barbara Spitzer, MD, Sarah Knutson, PhD, John Campbell, PhD, Heike Keilhack, PhD, Paul M Thomas, PhD, Neil L Kelleher, PhD, Omar Abdel-Wahab, Ari M. Melnick, MD, Scott A. Armstrong, MD PhD, Ross L. Levine, MD

Blood (2015) 126 (23): 713.

https://doi.org/10.1182/blood.V126.23.713.713

Published: 2015

Journal Articles

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Eytan M. Stein, MD, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Raoul Tibes, MD PhD, Jesus G. Berdeja, MD, Mojca Jongen-Lavrencic, MD PhD, Jessica K. Altman, MD, Hartmut Dohner, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Greg Fine, MS, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Bob Lowenberg, MD PhD, Martin S Tallman, MD

Blood (2015) 126 (23): 2547.

https://doi.org/10.1182/blood.V126.23.2547.2547

Published: 2015

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

Conditional Deletion of Asxl1 Results in Myelodysplasia

Omar Abdel-Wahab, M.D., Jie Gao, PhD, Mazhar Adli, PhD, Young Rock Chung, MSc, Richard Koche, PhD, Alan H. Shih, MD, PhD, Suveg Pandey, BSc, Lindsay M. La-Fave, PhD, Delphine Ndiaye-Lobry, Yu Sup Shin, BSc, Parva K. Bhatt, BSc, Jay P. Patel, Xinyang Zhao, PhD, Christopher Y. Park, MD, PhD, Jacob D. Jaffe, PhD, Bradley E. Bernstein, MD, PhD, Iannis Aifantis, PhD, Ross L. Levine

Blood (2012) 120 (21): 308.

https://doi.org/10.1182/blood.V120.21.308.308

Published: 2012

NARROW

Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism

Stag2 Regulates Hematopoietic Differentiation and Self-Renewal through Alterations in Gene Expression and Topological Control

The Lysine Histone Methyltransferase SETD2 Is Required for Appropriate Immunoglobulin VDJ Recombination

Functional Profiling of Patient AML Stem Cells Reveals Mechanisms of Epigenetic Plasticity Controlling Therapy Resistance

AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival

Targeting the DNA Damage Response Pathway in MLL- rearranged B-Acute Lymphoblastic Leukemias

Lineage Deconvolution Using Chromatin Accessibility and DNA Methylation Shows a Spectrum of Lineage Characteristics and Differentiation States across Acute Leukemias

LSD1 Inhibition Exerts Its Anti-Leukemic Effect By Recommissioning PU.1- and C/Ebpα-Dependent Enhancers in AML

Inhibition of MEK and DDR Pathways Induces Synergistic Killing of Novel Mll-Af4 B-ALL Model Harboring Activated Ras Mutations

An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL -Rearranged Leukemia to DOT1L Inhibition

Loss of Lysine Histone Methyltransferase Setd2 Disrupts Normal Hematopoiesis, Lineage Commitment and Reveals a Novel Role for H3K36me3 in Immunoglobulin VDJ Recombination

Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia

Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia

Non-Catalytic Role of SETD1A Regulates DNA Repair in Leukemia

BAP1 Loss Results in EZH2-Dependent Transformation in Myelodysplastic Syndromes

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Conditional Deletion of Asxl1 Results in Myelodysplasia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only